Want to see GB:GNS full AI Analyst Report?
Top Page
Genus plc
(LSE:GNS)
Select Model
Select Model
Rating:68Neutral
Price Target:
2,326.00 p
▲(1.13% Upside)
Action:Reiterated
Date:09/15/26
The score is supported most by improved financial strength and cash generation, plus a constructive earnings outlook and attractive low P/E valuation. These positives are tempered by weak technical momentum (below key moving averages with negative MACD) and the uneven/possibly non-recurring nature of recent profitability.
Positive Factors
Balance sheet deleveraging
Material debt reduction and higher equity have strengthened Genus's financial resilience and lowered leverage risk. A healthier capital structure should preserve flexibility to fund research, support customers, pursue growth opportunities, and maintain shareholder returns through the next several quarters.
Negative Factors
North American disease pressure
Livestock disease pressure is directly reducing customer production and royalty-linked revenue in North America. Management expects the headwind to continue into the first half of FY 2027, so recovery depends partly on normalization of operating conditions outside Genus's immediate control.
Read all positive and negative factors
Positive Factors
Negative Factors
Balance sheet deleveraging
Material debt reduction and higher equity have strengthened Genus's financial resilience and lowered leverage risk. A healthier capital structure should preserve flexibility to fund research, support customers, pursue growth opportunities, and maintain shareholder returns through the next several quarters.
Read all positive factors
Genus plc (GNS) vs. iShares MSCI United Kingdom ETF (EWC)
Market Cap
£1.42B
Dividend Yield1.53%
Average Volume (3M)188.99K
Price to Earnings (P/E)5.0
Beta (1Y)1.65
Revenue Growth-2.18%
EPS Growth1365.44%
CountryUK
Employees3,190
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)4.29
Shares Outstanding66,277,245
10 Day Avg. Volume237,080
30 Day Avg. Volume188,987
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)1.85
Price to Sales (P/S)2.16
P/FCF Ratio18.20
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
£2,803.33Price Target Upside21.88% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)1.03
Revenue Forecast (FY)£660.16M
Genus plc Business Overview & Revenue Model
Company Description
Genus plc is a global animal genetics company with operations spanning North America, Latin America, the UK, continental Europe, the Middle East, Russia, Africa, and Asia. The business is divided into three key segments: Genus PIC, Genus ABS, and ...
How the Company Makes Money
Genus makes money primarily by commercializing livestock genetics and associated services. A major revenue stream comes from PIC, where Genus sells and licenses pig breeding genetics—such as nucleus and grandparent breeding stock and related genet...
Genus plc Earnings Call Summary
Earnings Call Date:Sep 10, 2026
(Q4-2026)
| % Change Since: |
Next Earnings Date:Feb 25, 2027
Earnings Call Sentiment Positive
The call was strongly positive overall. Management reported substantial adjusted profit, EPS, free cash flow, margin, leverage, and return-on-capital improvements, alongside strong PIC China and ABS performance, PRP regulatory progress, capital returns, and a moderately higher FY 2027 profit outlook. These strengths were partly offset by disease pressure in North America, weak pork and dairy market conditions, expected moderation in Brazil and lower FY 2027 free cash flow, but the stated outlook remained for resilient underlying growth.Positive Updates
Strong Adjusted Profit and EPS Growth
FY 2026 adjusted profit before tax and adjusted earnings per share both increased by 35%. Adjusted profit before tax was reported as NOK 100.2 million and adjusted earnings per share reached 110.3p, including the £5.6 million BCA milestone receipt.
Negative Updates
Reported Revenue Decline
Revenue was NOK 658.1 million, 2% lower in actual currency, primarily reflecting the deconsolidation of PIC China following formation of the joint venture.
Read all updates
Q4-2026 Updates
Positive
Negative
Strong Adjusted Profit and EPS Growth
FY 2026 adjusted profit before tax and adjusted earnings per share both increased by 35%. Adjusted profit before tax was reported as NOK 100.2 million and adjusted earnings per share reached 110.3p, including the £5.6 million BCA milestone receipt.
Read all positive updates
Company Guidance
For FY 2027, the Group expects underlying adjusted PBT constant currency to be moderately higher year on year, in line with consensus expectations, with moderate adjusted operating profit growth for both PIC from a normalized base and ABS; Group PBT is expected to be second half weighted, with FY 2027 phasing a very similar flip around to FY 2026, where more than 50% was in the first half. FY 2027 free cash flow is expected to also be strong but lower than FY 2026, principally due to the China joint venture formation and a modest increase in net capital expenditure; research costs are expected to grow in FY 2027 albeit remaining below 3% of group revenue, underlying PRP costs are expected to increase further, and the VAP program is targeted to complete during the first half of FY 27. The FY 2027 tax rate is expected to be broadly similar to 27.2%, leverage is expected to be around the bottom end of the targeted range of 1 to 2 times, Brazil is probably going to see lower growth in FY 2027, and North America could see a return to growth in the second half of FY 2027 if there is more normalization.Genus plc Financial Statement Overview
Summary
Income Statement
64
Positive
Balance Sheet
78
Positive
Cash Flow
71
Positive
| Breakdown | Jun 2026 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 658.10M | 672.80M | 668.80M | 689.70M | 593.40M |
| Gross Profit | 658.10M | 672.80M | 178.70M | 239.30M | 226.00M |
| EBITDA | 128.20M | 93.70M | 73.70M | 87.50M | 79.80M |
| Net Income | 285.30M | 19.30M | 7.90M | 33.30M | 40.90M |
Balance Sheet | |||||
| Total Assets | 1.02B | 899.00M | 1.03B | 1.01B | 1.02B |
| Cash, Cash Equivalents and Short-Term Investments | 43.70M | 48.00M | 42.50M | 36.30M | 38.80M |
| Total Debt | 107.50M | 265.90M | 291.20M | 232.10M | 223.80M |
| Total Liabilities | 251.60M | 423.00M | 485.00M | 440.30M | 445.80M |
| Stockholders Equity | 766.70M | 475.60M | 548.20M | 569.40M | 578.50M |
Cash Flow | |||||
| Free Cash Flow | 78.00M | 48.60M | 5.10M | 15.20M | -7.80M |
| Operating Cash Flow | 90.50M | 67.20M | 29.80M | 50.40M | 34.30M |
| Investing Cash Flow | 79.00M | -13.80M | -19.30M | -30.90M | -67.20M |
| Financing Cash Flow | -175.30M | -46.60M | -2.80M | -18.20M | 21.90M |
Genus plc Technical Analysis
Negative
2300.00
Price Trends
2223.00
Negative
2220.20
Negative
2449.99
Negative
Market Momentum
-27.03
Negative
45.76
Neutral
53.70
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:GNS, the sentiment is Negative. The current price of 2300 is above the 20-day moving average (MA) of 2153.40, above the 50-day MA of 2223.00, and below the 200-day MA of 2449.99, indicating a bearish trend. The MACD of -27.03 indicates Negative momentum. The RSI at 45.76 is Neutral, neither overbought nor oversold. The STOCH value of 53.70 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GB:GNS.
Genus plc Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
79 Outperform | £87.52M | 11.80 | 65.83% | 8.96% | -8.21% | -5.27% | |
68 Neutral | £1.42B | 5.00 | 44.90% | 1.53% | -2.18% | 1365.44% | |
54 Neutral | £2.18B | -13.99 | -35.45% | ― | 14.80% | 16.88% | |
52 Neutral | £87.10M | -4.85 | -316.73% | ― | -56.10% | -16.77% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | £14.08M | -11.36 | -97.87% | ― | 7.38% | 44.13% | |
38 Underperform | £15.46M | -0.29 | -451.74% | ― | 33.37% | 86.41% |
* Healthcare Sector Average
GB:GNS
Genus plc
2,144.00
-323.91
-13.12%
GB:BVXP
Bioventix
1,675.00
-597.77
-26.30%
GB:OBD
Oxford BioDynamics
0.12
-0.44
-79.09%
GB:FAB
Fusion Antibodies Plc
11.25
-4.25
-27.42%
GB:4BB
4basebio UK Societas
562.50
-212.50
-27.42%
GB:ONT
Oxford Nanopore Technologies PLC
223.20
69.80
45.50%
Genus plc Corporate Events
Business Operations and StrategyStock Buyback
Genus boosts capital return with cancellation of latest share buyback
Positive
Sep 14, 2026
Genus plc has continued its programme of buying back its own shares, purchasing 67,153 ordinary shares through J.P. Morgan Securities over two trading days in September 2026. The company has confirmed that all of the repurchased shares will be can...
Business Operations and StrategyStock Buyback
Genus Launches £60m Share Buyback to Signal Confidence in Growth
Positive
Sep 10, 2026
Genus plc, the global animal genetics specialist, has launched a share buyback programme that will allow the repurchase of up to £60 million of its ordinary shares, with all bought-back shares to be cancelled, reducing the company’s cap...
Business Operations and StrategyStock BuybackDividendsFinancial Disclosures
Genus boosts profits, cuts leverage and launches £60m buyback after China JV
Positive
Sep 10, 2026
Genus reported a strong set of preliminary results for the year to 30 June 2026, with adjusted operating profit including joint ventures up 25 percent and adjusted profit before tax rising 35 percent despite a slight 2 percent decline in revenue. ...
Regulatory Filings and Compliance
Genus plc Confirms Updated Total Voting Rights and Share Capital
Neutral
Aug 3, 2026
Genus plc has confirmed that as of 31 July 2026 its issued share capital comprises 66,540,754 ordinary shares of 10 pence each, all carrying identical voting rights and with none held in treasury. This disclosure sets the reference point for inves...
Business Operations and StrategyFinancial Disclosures
Genus lifts FY26 outlook as Asia growth and China JV boost profits and cash
Positive
Jul 14, 2026
Genus plc, a global animal genetics specialist focused on dairy, beef and pork, reported stronger-than-expected trading for the year to 30 June 2026, driven by robust growth in its PIC pig genetics business in Asia and Latin America and double-dig...
Regulatory Filings and Compliance
Genus Director Celia Baxter Increases Stake with Share Purchase
Positive
Jun 29, 2026
Genus plc reported that non-executive director Celia Baxter has purchased 2,336 ordinary shares in the company on the London Stock Exchange at an average price of £21.39512 per share. The trade, conducted on 26 June 2026, was disclosed in lin...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.